This offers the potential for targeted drug therapy of clinically symptomatic visual hallucinations in patients with schizophrenia using acetylcholinesterase inhibition. Methods: A systematic ...

Cholinesterase inhibitors all inhibit the acetylcholinesterase enzyme, thereby increasing the amount of available acetylcholine. The differing pharmacodynamic and pharmacokinetic profiles of the ...

This article looks at the rationale behind the combined use of acetylcholinesterase inhibitors and the N-methyl-D-aspartate-receptor antagonist, memantine, from both preclinical and clinical ...

ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects.